Skip to main content
. 2015 Aug 1;9(8):NC01–NC04. doi: 10.7860/JCDR/2015/13277.6288

[Table/Fig-2]:

Clinical characteristics of patients with Anisoheropia

S. No. Age/Sex Amblyopic Eye Fellow Eye
BCVA Pre therapy Log Mar Units Prescription (SE)* BCVA Post therapy BCVA Pre therapy Log Mar Units Prescription (SE)* BCVA Post therapy
1. 14year/F 20/80 0.6 +2DS 20/20 20/20 00 - 20/20
2. 22year/M 20/200 1.0 +4.25DS 20/40 20/25 0.1 +1.50DS 20/20
3. 30year/F 20/125 0.8 +3.50DS 20/25 20/20 00 - 20/20
4. 16year/M 20/400 02 +5.25DS 20/40 20/20 00 +1.75DS 20/20
5. 24year/M 20/200 1.0 +4DS 20/40 20/20 00 +0.5DS 20/20
6. 19year/M 20/200 1.0 +3.5DS 20/20 20/20 00 - 20/20
7. 12year/M 20/200 1.0 +4DS 20/20 20/20 00 +1.5DS 20/20
8. 30year/F 20/63 0.5 +2DS 20/20 20/20 00 - 20/20
9. 17year/M 20/63 0.5 +1.75DS 20/20 20/20 00 - 20/20
10. 14year/M 20/125 0.8 +3.25DS 20/20 20/20 00 +0.5DS 20/20
11. 12year/F 20/80 0.6 +2.75DS 20/20 20/20 00 +0.75DS 20/20
12. 17year/F 20/125 0.8 +3.50DS 20/25 20/20 00 +0.50DS 20/20
13. 12year/F 20/63 0.5 +1DS 20/20 20/20 00 - 20/20
14. 20year/M 20/63 0.5 +1.75DS 20/20 20/20 00 - 20/20
15. 20year/M 20/200 1.0 +3DS 20/25 20/20 00 - 20/20
16. 13year/F 20/400 02 +4.5DS 20/40 20/25 0.1 +1.50DS 20/20
17. 12year/F 20/80 0.6 +2.25DS 20/20 20/20 00 - 20/20
18. 12year/M 20/125 0.8 +3.50DS 20/20 20/20 00 - 20/20
19. 27year/F 20/200 1.0 +2.75DS 20/25 20/20 00 - 20/20
20. 12year/M 20/200 1.0 +4.50DS 20/20 20/25 0.1 +2.25DS 20/25
21. 20year/M 20/63 0.5 +1.75DS 20/20 20/20 00 +0.25DS 20/20
22. 20year/F 20/125 0.8 +3.25DS 20/40 20/20 00 - 20/20
23. 22year/F 20/400 02 +5.50DS 20/40 20/20 00 - 20/20
24. 13year/M 20/200 1.0 +3DS 20/20 20/20 00 - 20/20

*Spherical Equivalent